Combs Andrew's Form 4 filing
Prelude Therapeutics Inc (PRLD) · filed Dec 26, 2024
- Accession no.
- 0001562180-24-008565
- Filed
- Dec 26, 2024
- Trade date
- Dec 20-23, 2024
- Filing delay
- 6 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $85.7K. It was filed 6 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Combs AndrewCIK 0001825005 | Officer (Chief Chemistry Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2024 | Common Stock | PPurchaseAcquired | +3,075 | $1.15 | +$3,536.25 | 317,623 | Direct | |
| Dec 23, 2024 | Common Stock | PPurchaseAcquired | +60,000 | $1.37F2 | +$82,200 | 377,623 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
Referenced by the price of 1 transaction in Table I.